Scholarlink

Background <p>The CXCR3-B receptor plays a crucial role in inducing apoptosis upon binding with its ligands. Here, we aimed to rationally design an ultra-short (5-base) DNA aptamer targeting the N-terminal domain of CXCR3-B and evaluate its therapeutic potential in Acute Lymphoblastic Leukemia (ALL).</p> Methods <p>An <i>in-silico</i> library of 32 pentanucleotide aptamers (comprising adenine and guanine) was constructed. The three-dimensional structure of the CXCR3-B N-terminus was modeled and docked with the aptamers, followed by targeted molecular docking and binding stability scoring to evaluate complex interactions. In vitro, Nalm-6 cells were treated with the lead aptamer (GAGGA), a scrambled control, and proteinase K. Cell viability, metabolic activity, and apoptosis were assessed via trypan blue, MTT, and Annexin V/PI flow cytometry. The expression of <i>BAX</i>, <i>P53</i>, and <i>CDKN1A</i> (p21) was quantified using qPCR.</p> Results <p>The GAGGA aptamer exhibited the highest binding affinity and complex stability in silico. In vitro, GAGGA at 600&#xa0;µM significantly reduced metabolic activity and viability after 24&#xa0;h compared with untreated and scrambled aptamer controls. The apoptotic cell ratio increased significantly (13.65% vs. 2.98% in control), accompanied by the significant upregulation of <i>BAX</i>, <i>P53</i>, and <i>CDKN1A</i>. Pre-treatment with proteinase K abolished these effects, confirming receptor-specific binding.</p> Conclusions <p>Our findings demonstrate that the ultra-short GAGGA aptamer specifically targets CXCR3-B and triggers apoptotic pathways in ALL cells. While the effective concentration is high, likely due to the lack of nuclease resistance in unmodified ultra-short oligonucleotides, this study provides a novel molecular scaffold for future aptamer-based ALL therapies following appropriate chemical modifications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Aptamer-mediated targeting of CXCR3-B in acute lymphoblastic leukemia nalm-6 cells: an in silico and in vitro study

  • 期刊论文

  • 发表日期：

    2026年7月27日

查看全文
  • Hossein Arezoomand,
  • Ali Jebali,
  • Hajar Mardani Valandani,
  • Maryam Nooshadokht,
  • Ali Bazi,
  • Ali Afgar,
  • Muhammad Hossein Ashoub,
  • Roohollah Mirzaee Khalilabadi

摘要

Background

The CXCR3-B receptor plays a crucial role in inducing apoptosis upon binding with its ligands. Here, we aimed to rationally design an ultra-short (5-base) DNA aptamer targeting the N-terminal domain of CXCR3-B and evaluate its therapeutic potential in Acute Lymphoblastic Leukemia (ALL).

Methods

An in-silico library of 32 pentanucleotide aptamers (comprising adenine and guanine) was constructed. The three-dimensional structure of the CXCR3-B N-terminus was modeled and docked with the aptamers, followed by targeted molecular docking and binding stability scoring to evaluate complex interactions. In vitro, Nalm-6 cells were treated with the lead aptamer (GAGGA), a scrambled control, and proteinase K. Cell viability, metabolic activity, and apoptosis were assessed via trypan blue, MTT, and Annexin V/PI flow cytometry. The expression of BAX, P53, and CDKN1A (p21) was quantified using qPCR.

Results

The GAGGA aptamer exhibited the highest binding affinity and complex stability in silico. In vitro, GAGGA at 600 µM significantly reduced metabolic activity and viability after 24 h compared with untreated and scrambled aptamer controls. The apoptotic cell ratio increased significantly (13.65% vs. 2.98% in control), accompanied by the significant upregulation of BAX, P53, and CDKN1A. Pre-treatment with proteinase K abolished these effects, confirming receptor-specific binding.

Conclusions

Our findings demonstrate that the ultra-short GAGGA aptamer specifically targets CXCR3-B and triggers apoptotic pathways in ALL cells. While the effective concentration is high, likely due to the lack of nuclease resistance in unmodified ultra-short oligonucleotides, this study provides a novel molecular scaffold for future aptamer-based ALL therapies following appropriate chemical modifications.